THANK YOU FOR YOUR INTEREST IN AMARIN.
If you are looking for information about VAZKEPA® (icosapent ethyl) in a specific country in Europe, please note that we have partnered with Recordati for the region.
On June 24, 2025 Amarin announced an exclusive license and supply agreement with Recordati S.p.A. under which Recordati will commercialize VAZKEPA® (icosapent ethyl) in Europe. Going forward, VAZKEPA will be available to eligible patients in Europe through the Recordati organisation.
If you have any questions about Amarin, you can reach out to us through our dedicated Contact Page here:
To report an adverse event, product complaints, request medical information or seek answers to general product or company related questions, you can also reach out directly to amarinconnect@amarincorp.com or connect with Amarin using local phone numbers. AmarinConnect representatives are ready to receive and respond to your request.
For further information about Amarin, don’t hesitate to visit our About Amarin section.
